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ReferencesUnderlying 
Pathophysiology
Of the non-Hodgkin’s lymphomas, FL is the 
second most frequent occurring lymphoma
in the US. Without signs and symptoms in 
early stages, FL is most often diagnosed in 
later stages. FL in most circumstances cannot 
be cured, but treatment involves alleviating 
symptoms.
Undergoing studies have made advances in 
understanding FL and providing treatment.
Studies have shown patients with FL with 
different biomarkers, respond better to 
different treatments (Barton, 2013). In 
clinical trials, researchers are using different 
methods of boosting patients’ immune 
systems to assist fighting FL including a 
vaccine (American Cancer Society, 
2016).
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Follicular lymphoma is a subtype of 
non-Hodgkin’s lymphoma. It is the second 
most frequent type of lymphoma in the 
United States (US). There is some debate 
on which treatment is better even though 
currently there is not a cure. Also risk 
factors have been linked to follicular 
lymphoma.
This topic was chosen because this 
author works with a nurse who has 
follicular lymphoma. It was diagnosed at a 
later stage and currently this nurse is 
debating on going through treatment or to 
keep observing by “watch and wait” (no 
treatment given but monitor bloodwork 
and computed tomography (CT) and 
positron emission tomography (PET) 
scans until symptomatic). She knows 
there is not a cure even with treatment.
Pathophysiological 
Process
Signs and Symptoms
Follicular lymphoma (FL) most 
commonly presents as a painless, 
slowly progressive adenopathy. 
Symptoms usually do not appear until 
disease reaches later stages. 
Systemic symptoms: 
Fever
Night sweats
Weight loss in excess of 10%
Asthenia (lack of energy or strength)
Bone marrow dysfunction: anemia, 
leukopenia, or thrombocytopenia
Involved lymph nodes are nontender, 
firm, and rubbery
Splenomegaly present in 50% of 
patients
Hepatosplenomegaly may occur
FL is defined as a proliferation of malignant 
germinal center B cells that are mixed with 
nonmalignant cells (T cells, follicular dendritic cells, 
and macrophages) and whose normal counterparts 
(centrocytes & centroblasts) represent the 
predominant cell types of the germinal cell reaction 
(Kridel, Sehn, & Gascoyne, 2012, p. 3424). The genetic 
hallmark of FL is the translocation T(14;18) resulting 
in the constitutive overexpression of the B-cell 
lymphoma 2 (bcl 2) protein, impairing the normal 
germinal center apoptotic program (Hiddle & Cheson, 
2014, p. 1388). The first genetic hit is believed to occur 
in the bone marrow during the early B cell 
development stage (Kridel et al., 2012, p. 3424). The 
naïve B cells carry the t(14;18) out of the bone marrow 
and into the secondary lymphoid tissue, where the B 
cells colonize and undergo germinal center reaction 
but survive due to their constitutive expression of bcl 2 
(Kridel et al., 2012, p. 3424). The bcl 2 may also rescue 
these cells from apoptosis due to weak B cell receptor 
(BCR) affinity (Kridel et al., 2012, p. 3424). Early FL 
progenitor acquire secondary genetic alterations by 
the influence of activation-induced cytidine deaminase 
(AID) (Kridel et al., 2012, p. 3425).
FL has different treatment options, from 
the observation for disease symptoms 
(watch and wait) to high dose 
chemotherapy (Goodrich, 2012). The 
disease is not curable and is 
characterized by multiple relapses 
(Loeffler et al., 2015, p. 456). Advanced 
practice nurses (APN) can educate 
patients and families on the disease 
process, explain testing and treatment 
options, along with assist patients with 
support for financial assistance and 
support groups. APNs can also discuss 
side effects of treatments and monitor 
labs and CT/PET scans for increased 
growth or return of disease.
Significance of Pathophysiology
FL is the most common low-grade non-Hodgkin lymphoma in the 
US with more than 14,000 cases diagnosed each year (Nabhan et 
al., 2015, p. 85). According to Freytes and Merten, FL constitutes 
approximately 20% of non-Hodgkin lymphoma (2016). FL is rare 
in children, but chances increase with age (median age is 60-65 
years) (Freytes & Merten, 2016). 
Risk factors have been associated with development of FL. 
Cigarette smoking, pesticides, first degree relative with non-
Hodgkin lymphoma, increased body mass index (BMI) as a young 
adult, and women with Sjogren syndrome (Linet et al., 2014). 
Viruses (Epstein-Barr virus, human T- cell lymphotropic virus and 
herpes virus associated with Kaposi sarcoma), chemicals 
(pesticides and hair dyes), and immunodeficient states have been 
linked to lymphomas (Freytes & Merten, 2016).
Most FL patients present at an advanced stage and have bone 
marrow involvement. Biopsy is needed for definite lymphoma 
diagnosis. After diagnosis, FL is further categorized into grades 
according to the number of centroblasts per high power field (hpf) 
(Freytes & Merten, 2016). The following is how FL is staged and 
graded.
Staging:
Stage 1 – one lymph node or area involved
Stage 2 – two or more involved lymph node areas on same side
Stage 3 – bilateral involved lymph node or areas 
Stage 4 – disseminated disease (bone marrow, liver, or central 
nervous system involvement)
Grading:
Grade 1 – 0-5 centroblasts per hpf
Grade 2 – 6/15 centroblasts per hpf
Grade 3 - >15 centroblasts per hpf
Figure 1. From: Rapidly Progressed Primary 
Intestinal Follicular Lymphoma with Elevation of 
Soluble Interleukin-2 Receptor Levels. 
Esophagogastroduodenoscopy revealed whitish 
mucosa in the duodenum before (a) and after 
spraying indigo carmine dye (b). Biopsy specimens 
contained small- to medium-sized lymphoma cells 
forming lymphoid follicles ((c), hematoxylin and 
eosin stain). Those cells were positive for CD20 
(d), CD10 (e), and BCL2 (f) but negative for CD3. 
Consequently, the diagnosis of follicular lymphoma 
was made.
Masaya Iwamuro, et al. Case Rep Oncol Med. 
2014;2014:549248.
HISTOLOGY: LYMPH NODE: LYMPHOMA, NODULAR 
OR FOLLICULAR MIXED LARGE AND SMALL CELL
